Civic Intelligence

Orphan Therapeutics Accelerator Inc

EIN 99-3630868 • 501(c)3 • Andover, MA

Profile

The specific and primary purpose of the Orphan Therapeutics Accelerator is to engage in charitable and scientific activities within the meaning of Section 501(c)(3) of the Code, including, but not limited to, the following activities: a. Providing, expanding access to, and resolving barriers to the development of therapeutic resources in the form of drugs, therapies, and other related treatments to rare diseases (collectively, the "Therapies"), so as to provide accessible treatments and potential cures to rare diseases that, otherwise, would not be available (such purposes, the "Charitable Purposes"). b. Addressing and resolving scientific barriers to development of the Therapies, which the Accelerator will accomplish via research as it acquires and shepherds the Therapies through late-stage clinical trials, so as to provide accessible treatments and potential cures for rare diseases without known and accessible treatments (such purposes, the "Scientific Purposes").

54 Morton StreetAndover, MA 01810

www.orphantxl.com

Siviq Scores

Precomputed percentiles relative to similar nonprofits. These scores are descriptive rather than judgmental.

Liabilities / Assets

Score unavailable

No value available

Liabilities-to-assets requires both liabilities and assets on the latest valid filing.

Source year 2024

Liabilities / Revenue

Score unavailable

No value available

Liabilities-to-revenue requires both liabilities and revenue on the latest valid filing.

Source year 2024

Net Margin

Score unavailable

No value available

Net margin requires both revenue and expenses on the latest valid filing.

Source year 2024

Top Officer Pay

99th percentile

$153,000

Higher top officer pay than 99% of similar nonprofits.

501(c)3 • <$500k nonprofits • Source year 2024

Asset Growth

Score unavailable

No value available

No earlier valid filing was available within the previous three public years.

Source year 2024

Revenue Growth

Score unavailable

No value available

No earlier valid filing was available within the previous three public years.

Source year 2024

Assets

$0

No earlier filing loaded for comparison.

Liabilities

$364,147

No earlier filing loaded for comparison.

Net Assets

-$364,147

No earlier filing loaded for comparison.

Revenue

$0

No earlier filing loaded for comparison.

Expenses

$364,147

No earlier filing loaded for comparison.

Net Income

-$364,147

No earlier filing loaded for comparison.

Trend Graphs

Balance Sheet Trend

Grouped bars show assets, liabilities, and net assets across loaded filings.

$400K$200K$0-$200K-$400KAssets 2024: $0Liabilities 2024: $364,147Net Assets 2024: -$364,1472024

Highlighted filing

2024

Assets$0
Liabilities$364,147
Net Assets-$364,147

Operations Trend

Revenue, expenses, and net income by year, with the latest filing highlighted.

$400K$200K$0-$200K-$400KRevenue 2024: $0Expenses 2024: $364,147Net Income 2024: -$364,1472024

Highlighted filing

2024

Revenue$0
Expenses$364,147
Net Income-$364,147

Filings

Balance SheetOperations
YearAssetsLiabilitiesNet AssetsRevenueExpensesNet Income
2024Detailed filing. Detailed filing data is available for this year.$0.00$3.64$3.64$0.00$3.64$3.64
Latest Filing Detail
Jump To
Filing Snapshot
Filing Period
Jan 1, 2024 to Dec 31, 2024
Signed
Nov 14, 2025
Return Version
2024v5.0
Gross Receipts
$0
Mission and Program Overview

Mission

The specific and primary purpose of the Orphan Therapeutics Accelerator is to engage in charitable and scientific activities within the meaning of Section 501(c)(3) of the Code, including, but not limited to, the following activities: a. Providing, expanding access to, and resolving barriers to the development of therapeutic resources in the form of drugs, therapies, and other related treatments to rare diseases (collectively, the "Therapies"), so as to provide accessible treatments and potential cures to rare diseases that, otherwise, would not be available (such purposes, the "Charitable Purposes"). b. Addressing and resolving scientific barriers to development of the Therapies, which the Accelerator will accomplish via research as it acquires and shepherds the Therapies through late-stage clinical trials, so as to provide accessible treatments and potential cures for rare diseases without known and accessible treatments (such purposes, the "Scientific Purposes").

Program Services

DescriptionGrantsExpenses
In 2024, the Orphan Therapeutics Accelerator was formed. In this initial year of operating, the organization developed a new model to bring rare disease programs that had been halted by for-profit companies through development so that these medicines could be made accessible to rare disease patients in need. We evaluated potential medicines, developed partnerships to support our model, and connected with potential funding sources.$0$282,597
Compensation and Service Providers

Employees

NameTitleFull / Part TimeBaseOtherTotal
Donald Craig MartinChief Executive Officer / Board DirectorPT$153,000-$153,000
Elizabeth WhiteSecretary-Executive Vice PresidentPT$135,000-$135,000
Deanna PorteroVice President, Partnerships And InnovationPT$13,780-$13,780
Nandan PadukoneTreasurer-Executive Vice President-$0--
James GeraghtyBoard Director-$0--
Susan KahnBoard Director-$0--
Filing and Contact Details

Filer

Filer Name
Orphan Therapeutics Accelerator Inc
EIN
99-3630868
Phone
2159158364
Address
54 Morton Street, Andover, MA 01810

Signing Officer

Name
Elizabeth White
Title
Secretary-Executive Vice President
Phone
2159158364
Signed
2025-11-14
Supplemental Narrative

Additional Explanations

Form 990-EZ, Part I, Line 16

Transportation, lodging, and conference registration expenses for attendance at relevant conferences.

Form 990-EZ, Part II, Line 26

The Orphan Therapeutics Accelerator was formed in 2024 and began operations under deferred payment agreements to Officers and legal advisors. This accrued a total of $364,147 in deferred payments in 2024 that were expected to be paid once funds were raised in 2025. Thus, $364,147 in liabilities are shown on the 2024 tax statement.

Raw XML Appendix189 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990EZ/ActivitiesNotPreviouslyRptInd00
IRS990EZ/BenefitsPaidToOrForMembersAmt00
IRS990EZ/BooksInCareOfDetail/BusinessName/BusinessNameLine1Txt0Danforth Advisors
IRS990EZ/BooksInCareOfDetail/PhoneNum06102092005
IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt0300 5th Avenue
IRS990EZ/BooksInCareOfDetail/USAddress/CityNm0Waltham
IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd0MA
IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd002451
IRS990EZ/CashSavingsAndInvestmentsGrp/BOYAmt00
IRS990EZ/CashSavingsAndInvestmentsGrp/EOYAmt00
IRS990EZ/ChgMadeToOrgnzngDocNotRptInd00
IRS990EZ/ContributionsGiftsGrantsEtcAmt00
IRS990EZ/CostOfGoodsSoldAmt00
IRS990EZ/CostOrOtherBasisExpenseSaleAmt00
IRS990EZ/DirectIndirectPltclExpendAmt00
IRS990EZ/DonorAdvisedFndsInd00
IRS990EZ/EngagedInExcessBenefitTransInd00
IRS990EZ/ExcessOrDeficitForYearAmt0-364147
IRS990EZ/FeesAndOtherPymtToIndCntrctAmt0353142
IRS990EZ/FiledScheduleAInd01
IRS990EZ/ForeignFinancialAccountInd00
IRS990EZ/ForeignOfficeInd00
IRS990EZ/Form1120PolFiledInd00
IRS990EZ/Form990TotalAssetsGrp/BOYAmt00
IRS990EZ/Form990TotalAssetsGrp/EOYAmt00
IRS990EZ/FundraisingGrossIncomeAmt00
IRS990EZ/GainOrLossFromSaleOfAssetsAmt00
IRS990EZ/GamingGrossIncomeAmt00
IRS990EZ/GrantsAndSimilarAmountsPaidAmt00
IRS990EZ/GrossProfitLossSlsOfInvntryAmt00
IRS990EZ/GrossReceiptsAmt00
IRS990EZ/GrossSalesOfInventoryAmt00
IRS990EZ/InfoInScheduleOPartIIInd0X
IRS990EZ/InfoInScheduleOPartIInd0X
IRS990EZ/InitialReturnInd0X
IRS990EZ/InvestmentIncomeAmt00
IRS990EZ/LandAndBuildingsGrp/BOYAmt00
IRS990EZ/LandAndBuildingsGrp/EOYAmt00
IRS990EZ/LobbyingActivitiesInd00
IRS990EZ/MadeLoansToFromOfficersInd00
IRS990EZ/MembershipDuesAmt00
IRS990EZ/MethodOfAccountingAccrualInd0X
IRS990EZ/NetAssetsOrFundBalancesBOYAmt00
IRS990EZ/NetAssetsOrFundBalancesEOYAmt0-364147
IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt00
IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt0-364147
IRS990EZ/OccupancyRentUtltsAndMaintAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt020
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt118
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt27.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt32
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt42
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt52
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt0153000
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt1135000
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt213780
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt30
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt40
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt50
IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm0Donald Craig Martin
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm1Elizabeth White
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm2Deanna Portero
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm3Nandan Padukone
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm4James Geraghty
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm5Susan Kahn
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt0Chief Executive Officer / Board Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt1Secretary-Executive Vice President
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt2Vice President, Partnerships and Innovation
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt3Treasurer-Executive Vice President
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt4Board Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt5Board Director
IRS990EZ/OperateHospitalInd00
IRS990EZ/Organization501c3Ind0X
IRS990EZ/OrganizationDissolvedEtcInd00
IRS990EZ/OrganizationHadUBIInd00
IRS990EZ/OtherAssetsTotalDetail/BOYAmt00
IRS990EZ/OtherAssetsTotalDetail/EOYAmt00
IRS990EZ/OtherChangesInNetAssetsAmt00
IRS990EZ/OtherExpensesTotalAmt011005
IRS990EZ/OtherRevenueTotalAmt00
IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt0NONE
IRS990EZ/PartVIOfCompOfHghstPdEmplTxt0NONE
IRS990EZ/PoliticalCampaignActyInd00
IRS990EZ/PrimaryExemptPurposeTxt0The specific and primary purpose of the Orphan Therapeutics Accelerator is to engage in charitable and scientific activities within the meaning of Section 501(c)(3) of the Code, including, but not limited to, the following activities: a. Providing, expanding access to, and resolving barriers to the development of therapeutic resources in the form of drugs, therapies, and other related treatments to rare diseases (collectively, the "Therapies"), so as to provide accessible treatments and potential cures to rare diseases that, otherwise, would not be available (such purposes, the "Charitable Purposes"). b. Addressing and resolving scientific barriers to development of the Therapies, which the Accelerator will accomplish via research as it acquires and shepherds the Therapies through late-stage clinical trials, so as to provide accessible treatments and potential cures for rare diseases without known and accessible treatments (such purposes, the "Scientific Purposes").
IRS990EZ/PrintingPublicationsPostageAmt00
IRS990EZ/ProgramServiceRevenueAmt00
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt0In 2024, the Orphan Therapeutics Accelerator was formed. In this initial year of operating, the organization developed a new model to bring rare disease programs that had been halted by for-profit companies through development so that these medicines could be made accessible to rare disease patients in need. We evaluated potential medicines, developed partnerships to support our model, and connected with potential funding sources.
IRS990EZ/ProgramSrvcAccomplishmentGrp/GrantsAndAllocationsAmt00
IRS990EZ/ProgramSrvcAccomplishmentGrp/ProgramServiceExpensesAmt0282597
IRS990EZ/ProhibitedTaxShelterTransInd00
IRS990EZ/RelatedOrganizationCtrlEntInd00
IRS990EZ/SalariesOtherCompEmplBnftAmt00
IRS990EZ/SaleOfAssetsGrossAmt00
IRS990EZ/ScheduleBNotRequiredInd0X
IRS990EZ/SchoolOperatingInd00
IRS990EZ/SpecialEventsDirectExpensesAmt00
IRS990EZ/SpecialEventsNetIncomeLossAmt00
IRS990EZ/StatesWhereCopyOfReturnIsFldCd0MA
IRS990EZ/SubjectToProxyTaxInd00
IRS990EZ/SumOfTotalLiabilitiesGrp/BOYAmt00
IRS990EZ/SumOfTotalLiabilitiesGrp/EOYAmt0364147
IRS990EZ/TanningServicesProvidedInd00
IRS990EZ/TaxImposedOnOrganizationMgrAmt00
IRS990EZ/TaxImposedUnderIRC4911Amt00
IRS990EZ/TaxImposedUnderIRC4912Amt00
IRS990EZ/TaxImposedUnderIRC4955Amt00
IRS990EZ/TaxReimbursedByOrganizationAmt00
IRS990EZ/TotalExpensesAmt0364147
IRS990EZ/TotalProgramServiceExpensesAmt0282597
IRS990EZ/TotalRevenueAmt00
IRS990EZ/TransactionWithControlEntInd00
IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd00
IRS990EZ/TypeOfOrganizationCorpInd0X
IRS990EZ/WebsiteAddressTxt0www.orphantxl.com
IRS990ScheduleA/First5Years170Ind0X
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearAmt00
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus1YearAmt00
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus2YearsAmt00
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus3YearsAmt00
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus4YearsAmt00
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/TotalAmt00
IRS990ScheduleA/GovtFurnSrvcFcltsVl170Grp/CurrentTaxYearAmt00
IRS990ScheduleA/GovtFurnSrvcFcltsVl170Grp/CurrentTaxYearMinus1YearAmt00
IRS990ScheduleA/GovtFurnSrvcFcltsVl170Grp/CurrentTaxYearMinus2YearsAmt00
IRS990ScheduleA/GovtFurnSrvcFcltsVl170Grp/CurrentTaxYearMinus3YearsAmt00
IRS990ScheduleA/GovtFurnSrvcFcltsVl170Grp/CurrentTaxYearMinus4YearsAmt00
IRS990ScheduleA/GovtFurnSrvcFcltsVl170Grp/TotalAmt00
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearAmt00
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus1YearAmt00
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus2YearsAmt00
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus3YearsAmt00
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus4YearsAmt00
IRS990ScheduleA/GrossInvestmentIncome170Grp/TotalAmt00
IRS990ScheduleA/GrossReceiptsRltdActivitiesAmt00
IRS990ScheduleA/OtherIncome170Grp/CurrentTaxYearAmt00
IRS990ScheduleA/OtherIncome170Grp/CurrentTaxYearMinus1YearAmt00
IRS990ScheduleA/OtherIncome170Grp/CurrentTaxYearMinus2YearsAmt00
IRS990ScheduleA/OtherIncome170Grp/CurrentTaxYearMinus3YearsAmt00
IRS990ScheduleA/OtherIncome170Grp/CurrentTaxYearMinus4YearsAmt00
IRS990ScheduleA/OtherIncome170Grp/TotalAmt00
IRS990ScheduleA/PublicOrganization170Ind0X
IRS990ScheduleA/PublicSupportTotal170Amt00
IRS990ScheduleA/SubstantialContributorsTotAmt00
IRS990ScheduleA/TaxRevLeviedOrgnztnlBnft170Grp/CurrentTaxYearAmt00
IRS990ScheduleA/TaxRevLeviedOrgnztnlBnft170Grp/CurrentTaxYearMinus1YearAmt00
IRS990ScheduleA/TaxRevLeviedOrgnztnlBnft170Grp/CurrentTaxYearMinus2YearsAmt00
IRS990ScheduleA/TaxRevLeviedOrgnztnlBnft170Grp/CurrentTaxYearMinus3YearsAmt00
IRS990ScheduleA/TaxRevLeviedOrgnztnlBnft170Grp/CurrentTaxYearMinus4YearsAmt00
IRS990ScheduleA/TaxRevLeviedOrgnztnlBnft170Grp/TotalAmt00
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearAmt00
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus1YearAmt00
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus2YearsAmt00
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus3YearsAmt00
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus4YearsAmt00
IRS990ScheduleA/TotalCalendarYear170Grp/TotalAmt00
IRS990ScheduleA/TotalSupportAmt00
IRS990ScheduleA/UnrelatedBusinessNetIncm170Grp/CurrentTaxYearAmt00
IRS990ScheduleA/UnrelatedBusinessNetIncm170Grp/CurrentTaxYearMinus1YearAmt00
IRS990ScheduleA/UnrelatedBusinessNetIncm170Grp/CurrentTaxYearMinus2YearsAmt00
IRS990ScheduleA/UnrelatedBusinessNetIncm170Grp/CurrentTaxYearMinus3YearsAmt00
IRS990ScheduleA/UnrelatedBusinessNetIncm170Grp/CurrentTaxYearMinus4YearsAmt00
IRS990ScheduleA/UnrelatedBusinessNetIncm170Grp/TotalAmt00
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt0Transportation, lodging, and conference registration expenses for attendance at relevant conferences.
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt1The Orphan Therapeutics Accelerator was formed in 2024 and began operations under deferred payment agreements to Officers and legal advisors. This accrued a total of $364,147 in deferred payments in 2024 that were expected to be paid once funds were raised in 2025. Thus, $364,147 in liabilities are shown on the 2024 tax statement.
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc0Form 990-EZ, Part I, Line 16
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc1Form 990-EZ, Part II, Line 26
ReturnHeader/BuildTS02025-03-06 01:10:19Z
ReturnHeader/BusinessOfficerGrp/PersonNm0Elizabeth White
ReturnHeader/BusinessOfficerGrp/PersonTitleTxt0Secretary-Executive Vice President
ReturnHeader/BusinessOfficerGrp/PhoneNum02159158364
ReturnHeader/BusinessOfficerGrp/SignatureDt02025-11-14
ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt0ORPHAN THERAPEUTICS ACCELERATOR INC
ReturnHeader/Filer/BusinessNameControlTxt0ORPH
ReturnHeader/Filer/EIN0993630868
ReturnHeader/Filer/PhoneNum02159158364
ReturnHeader/Filer/USAddress/AddressLine1Txt054 Morton Street
ReturnHeader/Filer/USAddress/CityNm0Andover
ReturnHeader/Filer/USAddress/StateAbbreviationCd0MA
ReturnHeader/Filer/USAddress/ZIPCd001810
ReturnHeader/IRSResponsiblePrtyInfoCurrInd01
ReturnHeader/ReturnTs02025-11-14T11:08:42-07:00
ReturnHeader/ReturnTypeCd0990EZ
ReturnHeader/TaxPeriodBeginDt02024-01-01
ReturnHeader/TaxPeriodEndDt02024-12-31
ReturnHeader/TaxYr02024

Document Assets

No mirrored PDF or thumbnail assets are attached yet.